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Introduction {#sec001}
============

The number of people diagnosed with diabetes worldwide has increased exponentially. However, it is currently not possible to directly treat the cause of diabetes. Type 1 diabetes (T1D) results from β-cell destruction by an autoimmune reaction that leads to insulin deficiency, and type 2 diabetes (T2D) is caused by insulin resistance and β-cell failure \[[@pone.0150981.ref001]\]. Therefore, insufficient insulin secretion due to β-cell loss is the common and major component in the pathogenesis of T1D and T2D, and decreased β-cell survival and growth are the primary mechanisms for β-cell loss \[[@pone.0150981.ref001]\]. The β-cell mass, which is governed by balancing β-cell death and proliferation, plays an essential role in maintaining optimal glucose homeostasis by determining the amount of insulin that is secreted into blood. Therefore, identifying the parameters that regulate β-cell death and proliferation and understanding their molecular mechanisms are especially important, and many molecules and signaling pathways have been identified. Among them, cyclin D2 and Bcl-2 are essential molecules in the regulation of β-cell growth and survival. Cyclin D2 is an essential regulator of β-cell expansion and stimulates cell cycle progression from G1 to S phase. Additionally, cyclin D2-deficient mice showed reduced β-cell growth and glucose intolerance \[[@pone.0150981.ref002]--[@pone.0150981.ref004]\]. The anti-apoptotic protein Bcl-2 is an essential molecule in the regulation of β-cell death. An imbalance between pro-apoptotic and anti-apoptotic Bcl-2 family proteins causes β-cell death via the mitochondrial pathway, and overexpression of Bcl-2 protects β cells from cytokine- and lipotoxic stress-induced cell death \[[@pone.0150981.ref005]--[@pone.0150981.ref007]\].

Because insulin is a key hormone that regulates not only energy homeostasis but also β-cell proliferation and death \[[@pone.0150981.ref008]--[@pone.0150981.ref010]\], many studies have focused on identifying factors that influence the insulin signaling pathway. Our recent studies have shown that the cannabinoid 1 receptor (CB1R), a G protein-coupled receptor that is activated by endogenous cannabinoids (ECs), is present in pancreatic β cells, in which its activation directly inhibits insulin receptor kinase activity by binding to the tyrosine kinase domain of the insulin receptor \[[@pone.0150981.ref011],[@pone.0150981.ref012]\]. Activation of CB1Rs by ECs and synthetic cannabinoids induce β-cell death and cell cycle arrest by inhibiting insulin receptor signaling via IRS2-AKT-BAD and IRS2-AKT-p27, respectively \[[@pone.0150981.ref011],[@pone.0150981.ref012]\]. Additionally, it has been reported that CB1Rs induce cell cycle arrest and death by inhibiting the PI3K-AKT cascade in various types of cancer cells \[[@pone.0150981.ref013]--[@pone.0150981.ref015]\]. Furthermore, treatment of cancer cells with the synthetic cannabinoid WIN55,212--2 led to the dose-dependent down-regulation of both cyclin D2 and Bcl-2 \[[@pone.0150981.ref015]\]. However, whether CB1Rs influence β-cell growth and survival by regulating the levels of cyclin D2 and Bcl-2 remains unclear. Here, we demonstrate that CB1R activation induces β-cell death and cell cycle arrest at G1 phase by decreasing Bcl-2 and cyclin D2 levels, respectively, both *in vitro* and *in vivo*.

Materials and Methods {#sec002}
=====================

Materials and Reagents {#sec003}
----------------------

AM251(N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide),WIN55,212-2(\[(3R)-2,3-dihydro-5-methyl-3-(4 morpholinylmethyl)pyrrolo\[1,2,3-de\]-1,4-benzoxazin-6-yl\]-1-naphthalenyl-methanone) and streptozotocin (STZ) (2-deoxy-2-\[\[(methylnitrosoamino)carbonyl\] amino\]-D-glucose) were purchased from Cayman Chemical. Rimonabant (biaryl pyrazole N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide) was synthesized at Ajou University. Antibodies against caspase-3, cyclin D2, and Bcl-2 were purchased from Cell Signaling Technology. An antibody against β-actin was purchased from Abcam. Antibody against Bax was purchased from Santa Cruz. Anti-mouse and anti-rabbit secondary horseradish peroxidase conjugate (HRP) was obtained from Bio-Rad Laboratories.

Cell Culture and Treatment {#sec004}
--------------------------

The mouse pancreatic β cell lines MIN6 and βTC6 were cultured in Dulbecco's modified Eagle's medium supplemented with 10% heat-inactivated fetal bovine serum and 1% antibiotic penicillin and streptomycin and were maintained under standard cell culture conditions at 37°C and 5% CO2 in a humid environment. Cells were treated with WIN55,212--2 at 0, 1, 2.5, and 5 μM for 24 or 48 h in DMEM with 0.5% FBS with or without AM251.

Cell Viability Assay {#sec005}
--------------------

Cell viability was determined by MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphenyl)-2H- tetrazolium, inner salt) assay (Cell Titer 96 AQueous One Solution Cell Proliferation Assay; Promega). MIN6 and βTC6 cells were plated on 96-well plates and allowed to adhere to the plates overnight. Cells were treated with WIN-55,212--2 (0, 1, 2.5, 5 μM) for 24 h, followed by incubation with MTS dye for 2 h. Absorbance was determined at 490 nm using iMark (Bio-Rad).

Western Blot Analysis {#sec006}
---------------------

Whole cell lysates were prepared using modified radioimmune precipitation assay buffer (10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% NonidetP-40, 1 mM EDTA, and 0.1% SDS), separated by electrophoresis in SDS-containing polyacrylamide gels, and transferred onto PVDF membranes (Millipore). Incubation with primary antibodies against caspase-3, cyclin D2, Bcl-2, Bax, and β-actin was followed by incubations with the appropriate secondary antibodies conjugated with HRP.

Cell Cycle Analysis by Flow Cytometry {#sec007}
-------------------------------------

Cells were plated at a density of 1x10^6^ cells on 6-well culture dishes. After an overnight incubation, cells were treated with WIN-55,212--2 (1.0, 2.5, 5.0 μM) for 48 h, washed twice with cold phosphate-buffer saline (PBS), detached with 0.25% trypsin-EDTA, and pelleted. The pellet was suspended in cold PBS, fixed in a final concentration of 70% ethanol for 1 h at 4°C, washed with cold PBS, and incubated with 100 μg/ml RNase A for 15 min at room temperature. Nuclei were stained with 50 μg/ml propidium iodide (PI; Sigma-Aldrich) for 30 min at 4°C in the dark. Samples were analyzed by flow cytometry using a fluorescence activated cell sorter (FACS). Results were analyzed using Mod-Fit LT software (Verity Software House, Topsham, ME) to determine cell cycle distribution.

Animal Experiments {#sec008}
------------------

All animal experiments were carried out in compliance with the protocol specifically approved for this study by the Ajou University Animal Care and Use Committee. *CB1R−/−* mice and their wild-type littermates were developed and backcrossed into a C57Bl/6J background, as previously described \[[@pone.0150981.ref016]\]. For regeneration experiments, low-dose (50 mg/kg) STZ was administered by daily i.p. injection into 2-month-old CD1 (Fig A in [S1 File](#pone.0150981.s001){ref-type="supplementary-material"}) or *CB1R−/−* and *CB1R+/+* mice (n = 5 per group) for 5 days (Fig B in [S1 File](#pone.0150981.s001){ref-type="supplementary-material"}). DMSO or AM251 (10 mg/kg) was then administered into CD1 mice by daily i.p injection without STZ. Three weeks after STZ withdrawal, mice were euthanized with a lethal dose of isoflurane and pancreata were collected for the metabolic and morphological analyses. DMSO or rimonabant (5 mg/kg) was administrated by daily intraperitoneal (i.p.) injection into 6-week-old *db/db* mice (n = 5 per group) for 4 weeks (Fig C in [S1 File](#pone.0150981.s001){ref-type="supplementary-material"}). Pancreata were rapidly dissected, fixed, and sectioned at a thickness of 7 μm. After antigen unmasking, the slides were blocked with 5% bovine serum albumin (BSA)/PBS and incubated at 4°C with a specific primary antibody, followed by secondary antibodies along with DAPI, in some cases, for nuclear staining. Slides were viewed with a Leica DMRBE microscope equipped with a 400X objective lens. Signal intensity was assessed using ImageJ software (<http://rsb.info.nih.gov/ij/>).

Statistical Analysis {#sec009}
--------------------

Quantitative data are presented as the mean ± SEM. Differences between mean values were compared statistically by Student's *t*-test. Comparisons were performed using GraphPad Prism (GraphPad Software) and Microsoft Excel 2010. A *P* value \< 0.05 was considered statistically significant.

Results and Discussion {#sec010}
======================

Activation of CB1R with WIN55,212--2 leads to decreased β cell survival {#sec011}
-----------------------------------------------------------------------

We first investigated the effects of the synthetic CB1R agonist WIN55,212--2 on pancreatic β-cell viability. Treatment of mouse insulinoma MIN6 cells with WIN55,212--2 caused morphological changes characteristic of apoptosis, including cell rounding, in a dose-dependent manner ([Fig 1A](#pone.0150981.g001){ref-type="fig"}). Additionally, the viability of MIN6 cells dose-dependently decreased with WIN55,212--2 treatment ([Fig 1B](#pone.0150981.g001){ref-type="fig"}). Similar effects of WIN55,212--2 on morphological changes ([Fig 1C](#pone.0150981.g001){ref-type="fig"}) and viability ([Fig 1D](#pone.0150981.g001){ref-type="fig"}) were observed in another mouse insulinoma cell line (βTC6). The effects of WIN55,212--2 on viability were prevented by AM251, a selective CB1R antagonist ([Fig 1E](#pone.0150981.g001){ref-type="fig"}), suggesting that these effects are mediated by CB1Rs. We next examined whether WIN55,212--2 regulates cell cycle progression in pancreatic β-cell lines. To analyze cell cycle distribution, DNA content analysis was performed with PI staining and subsequent FACS analysis after treatment with WIN55,212--2. As shown in [Fig 1F](#pone.0150981.g001){ref-type="fig"}, treatment of βTC6 cells with WIN55,212--2 led to an increase in the proportion of cells in G1 phase and a decrease in the proportion of cells in S phase. These results indicate that activation of CB1R by WIN55,212--2 induces cell cycle arrest at G1 phase in pancreatic β cells.

![The synthetic CB1R agonist WIN55,212--2 leads to decreased cell viability and increased G1 arrest in pancreatic β-cell lines.\
(A) Representative images of MIN6 cells exposed to WIN55,212--2. Scale bar, 50 μm. (B) The relative cell viability of MIN6 cells was determined by MTS assay 24 h after treatment with WIN55,212--2. Scale bar, 50 μm. (C) Representative images of βTC6 cells exposed to WIN55,212--2. (D) The relative cell viability of βTC6 cells was determined by MTS assay 24 h after treatment with WIN55,212--2. (E) The relative cell viability of MIN6 cells exposed to WIN55,212--2 with or without a CB1R inverse agonist AM251. MIN6 cells were exposed to WIN55,212--2 with or without AM251 for 24 h, and relative cell viability was determined by MTS assay. (F) WIN55,212--2 treatment in βTC6 cells increases the proportion of cells in G0/G1 phase. βTC6 cells exposed to WIN55,212--2 for 24 h were analyzed using a fluorescence activated cell sorter (FACS). Data are shown as the mean ± SEM from three independent experiments. \**P*\< 0.05; \*\**P*\< 0.01.](pone.0150981.g001){#pone.0150981.g001}

WIN55,212--2 decreases Bcl-2 and cyclin D2 expression in pancreatic β cells {#sec012}
---------------------------------------------------------------------------

Because cyclin D2 and Bcl-2 are pivotal molecules in the regulation of β-cell growth and survival \[[@pone.0150981.ref002]--[@pone.0150981.ref007]\], we next investigated the potential role of these molecules as a/the mediator of WIN55,212-2-controlled β-cell growth and survival. Consistent with our previous results ([Fig 1](#pone.0150981.g001){ref-type="fig"}), WIN55,212--2 induced caspase-3 activation in βTC6 cells in a dose-dependent manner ([Fig 2A](#pone.0150981.g002){ref-type="fig"}). WIN55,212--2 caused a dose-dependent decrease in the levels of both cyclin D2 and Bcl-2 in βTC6 cells ([Fig 2B](#pone.0150981.g002){ref-type="fig"}). Similar effects of WIN55,212--2 on caspase-3 activation and cyclin D2 and Bcl-2 levels were also observed in MIN6 cells (data not shown). These results suggest that WIN55,212-2-induced cell cycle arrest and cell death might be mediated by decreasing cyclin D2 and Bcl-2 levels, respectively.

![Effects of WIN55,212--2 treatment on the expression of Bcl-2 and cyclin D2 in βTC6 cells.\
βTC6 cells exposed to WIN55,212--2 for 24 h were subjected to western blot analysis for cleaved caspase-3 (A) or cyclin D2 and Bcl-2 (B). Relative densities for the indicated proteins are shown on the right. Data are shown as the mean ± SEM from three independent experiments. \**P*\< 0.05; \*\**P*\< 0.01.](pone.0150981.g002){#pone.0150981.g002}

CB1R blockade in diabetic mouse models increases Bcl-2 and cyclin D2 levels in pancreatic β cells {#sec013}
-------------------------------------------------------------------------------------------------

Our previous report demonstrated that the pharmacological and genetic blockade of CB1Rs has beneficial effects on β-cell growth and survival in mouse models of T1D \[[@pone.0150981.ref012]\]. Multiple injections of low-dose STZ cause insulin-dependent diabetes and produce a progressive increase in blood glucose levels due to selective β-cell destruction, and over time, the remaining β cells attempt to survive and proliferate \[[@pone.0150981.ref017],[@pone.0150981.ref018]\]. Compared with control mice, genetic deletion and pharmacological blockade of CB1Rs in STZ-injected mice lead to decreased blood glucose levels and increased β-cell growth and survival resulting from decreased levels of cyclin-dependent kinase inhibitor p27 and active caspase-3 caused by enhanced insulin signaling via the IRS2-AKT pathway \[[@pone.0150981.ref012]\]. Similar effects were also observed in AM251-injected normal and *db/db* mice \[[@pone.0150981.ref011]\]. Thus, using pancreata from those mice, we further examined whether the increased β-cell survival and growth seen following CB1R blockade in these mice are associated with any changes in the expression levels of Bcl-2 and cyclin D2. As shown in [Fig 3A](#pone.0150981.g003){ref-type="fig"}, daily injection of AM251 for 3 weeks in normal mice led to significantly increased levels of Bcl-2 in pancreatic β cells compared with DMSO-treated mice. Additionally, CB1R blockade by AM251 in STZ-injected mice increased the amount of Bcl-2 in pancreatic β cells compared with DMSO-treated mice ([Fig 3B](#pone.0150981.g003){ref-type="fig"}), and STZ-injected CB1R-null (*CB1R-/-*) mice also showed enhanced levels of Bcl-2 in pancreatic β cells compared with STZ-injected *CB1R+/+* mice ([Fig 3C](#pone.0150981.g003){ref-type="fig"}). Similar to Bcl-2, the levels of cyclin D2 in pancreatic β cells of normal mice were also significantly increased by AM251 ([Fig 4A](#pone.0150981.g004){ref-type="fig"}). Furthermore, CB1R blockade by AM251 in STZ-injected mice also significantly increased cyclin D2 levels in pancreatic β cells ([Fig 4B](#pone.0150981.g004){ref-type="fig"}), and a similar pattern was evident in pancreatic sections from STZ-injected *CB1R-/-* mice ([Fig 4C](#pone.0150981.g004){ref-type="fig"}).

![Blockade of CB1Rs in normal and STZ-treated mice increases Bcl-2 levels in β cells.\
(A) Representative images for insulin and Bcl-2 in β cells of DMSO- and AM251-injected normal mice. The relative signal intensity for Bcl-2 in β cells is shown on the right. (B) Representative images for insulin and Bcl-2 in β cells of DMSO- and AM251-injected mice after STZ treatment. The relative signal intensity for Bcl-2 in β cells is shown on the right. (C) Representative images for insulin and Bcl-2 in β cells of *CB1R+/+* and *CB1R-/-* mice 4 weeks after STZ treatment. The relative signal intensity for Bcl-2 in β cells is shown on the right. Data are shown as the mean ± SEM from n = 3--5 animals per group. \**P*\< 0.05; \*\**P*\< 0.01. Scale bar, 50 μm.](pone.0150981.g003){#pone.0150981.g003}

![Blockade of CB1Rs in normal and STZ-treated mice increases cyclin D2 levels in β cells.\
(A) Representative images for insulin and cyclin D2 in β cells of DMSO- and AM251-injected normal mice. The relative signal intensity for cyclin D2 in β cells is shown on the right. (B) Representative images for insulin and cyclin D2 in β cells of DMSO- and AM251-injected mice after STZ treatment. The relative signal intensity for cyclin D2 in β cells is shown on the right. (C) Representative images for insulin and cyclin D2 in β cells of *CB1R+/+* and *CB1R-/-* mice 4 weeks after STZ treatment. The relative signal intensity for cyclin D2 in β cells is shown on the right. Data are shown as the mean ± SEM from n = 3--5 animals per group. \**P*\< 0.05; \*\**P*\< 0.01. Scale bar, 50 μm.](pone.0150981.g004){#pone.0150981.g004}

The pharmacological blockade of CB1Rs in the T2D mouse model resulted in decreased blood glucose levels as well as increased intra-islet insulin content and β-cell mass due to enhanced β-cell proliferation \[[@pone.0150981.ref011]\]. Thus, we then investigated the expression levels of Bcl-2 and cyclin D2 in pancreatic β cells of *db/db* mice. The Bcl-2 level was reduced in pancreatic β cells of *db/db* mice compared with normal mice ([Fig 5A](#pone.0150981.g005){ref-type="fig"}). Daily injection of another selective CB1R antagonist (rimonabant) for 4 weeks in *db/db* mice led to significantly increased levels of Bcl-2 in pancreatic β cells compared with DMSO-treated mice ([Fig 5A](#pone.0150981.g005){ref-type="fig"}). A similar pattern for cyclin D2 was also observed in pancreatic β cells of rimonabant-injected *db/db* mice ([Fig 5B](#pone.0150981.g005){ref-type="fig"}). These results suggest that the effects of CB1R blockade on β-cell growth and survival are mediated, at least in part, by enhanced Bcl-2 and cyclin D2 levels.

![Blockade of CB1Rs in *db/db* mice increases Bcl-2 and cyclin D2 levels in β cells.\
(A) Representative images for insulin and Bcl-2 in β cells of normal and DMSO- or rimonabant-injected *db/db* mice. The relative signal intensity for Bcl-2 in β cells is shown on the right. (B) Representative images for insulin and cyclin D2 in β cells of normal and DMSO- or rimonabant-injected *db/db* mice. The relative signal intensity for cyclin D2 in β cells is shown on the right. Data are shown as the mean ± SEM from n = 5 animals per group. \**P*\< 0.05; \*\**P*\< 0.01. Scale bar, 50 μm.](pone.0150981.g005){#pone.0150981.g005}

CB1Rs play critical roles in regulation of β-cell mass and function by influencing insulin receptor signaling pathway \[[@pone.0150981.ref011],[@pone.0150981.ref012],[@pone.0150981.ref019]\]. Recent reports have shown that activation of CB1Rs by ECs and synthetic cannabinoids inhibited insulin receptor signaling, resulting in reduced β-cell mass \[[@pone.0150981.ref011],[@pone.0150981.ref012]\]. The serine/threonine kinase AKT is the primary mediator of insulin receptor signaling and many downstream targets of AKT have been identified that may underlie the ability of this cascade to regulate β-mass. It has been well known that AKT directly phosphorylate several crucial downstream molecules that mediate cell survival and proliferation signals, such as pro-apoptotic protein BAD, forkhead transcription factor FoxO1, and cyclin-dependent kinase inhibitor p27, leading to the suppression of the cell death and growth arrest signals \[[@pone.0150981.ref020]--[@pone.0150981.ref024]\]. Consistently, our previous studies have shown that activation of CB1Rs induces β-cell death and cell cycle arrest by inhibiting AKT-mediated phosphorylation of BAD and p27, respectively \[[@pone.0150981.ref011],[@pone.0150981.ref012]\]. Both cyclin D2 and Bcl-2 are also crucial downstream targets of AKT that play essential roles in regulation of β-cell mass \[[@pone.0150981.ref003]--[@pone.0150981.ref007],[@pone.0150981.ref025],[@pone.0150981.ref026]\]. Therefore, our data suggest that CB1Rs could regulate the expression of cyclin D2 and Bcl-2 by influencing insulin receptor signaling via IRS2-AKT cascade.

Conclusions {#sec014}
===========

In the present report, we provide evidence for a molecular mechanism by which CB1Rs regulate β-cell growth and survival through influencing cyclin D2 and Bcl-2. We found that activation of CB1R leads to a decrease in the expression of cyclin D2 and Bcl-2, in turn inducing cell cycle arrest in G0/G1 phase and caspase-3-dependent apoptosis both *in vitro* and *in vivo*. Taken together, these findings suggest involvement of Bcl-2 and cyclin D2 in the regulation of β-cell survival and growth by CB1Rs. Further studies examining the direct relationship between EC-induced β-cell death and Bcl-2 as well as EC-induced β-cell growth arrest and cyclin D2 are warranted, which would contribute to identify the exact mechanism by which CB1Rs regulate β-cell growth and survival.
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======================
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